IL118974A - History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them - Google Patents

History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL118974A
IL118974A IL11897496A IL11897496A IL118974A IL 118974 A IL118974 A IL 118974A IL 11897496 A IL11897496 A IL 11897496A IL 11897496 A IL11897496 A IL 11897496A IL 118974 A IL118974 A IL 118974A
Authority
IL
Israel
Prior art keywords
estra
substituted phenyl
hydroxy
derivative
diene
Prior art date
Application number
IL11897496A
Other languages
English (en)
Hebrew (he)
Other versions
IL118974A0 (en
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL118974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL118974A0 publication Critical patent/IL118974A0/xx
Publication of IL118974A publication Critical patent/IL118974A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11897496A 1995-08-17 1996-07-29 History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them IL118974A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202229 1995-08-17

Publications (2)

Publication Number Publication Date
IL118974A0 IL118974A0 (en) 1996-10-31
IL118974A true IL118974A (en) 2001-09-13

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11897496A IL118974A (en) 1995-08-17 1996-07-29 History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them

Country Status (26)

Country Link
US (1) US6011025A (de)
EP (1) EP0763541B1 (de)
JP (1) JP3977462B2 (de)
KR (1) KR100445376B1 (de)
CN (1) CN1129602C (de)
AR (1) AR003982A1 (de)
AT (1) ATE182596T1 (de)
AU (1) AU711369B2 (de)
BR (1) BR9603429A (de)
CA (1) CA2182771C (de)
CZ (1) CZ287740B6 (de)
DE (1) DE69603425T2 (de)
DK (1) DK0763541T3 (de)
ES (1) ES2137625T3 (de)
GR (1) GR3031116T3 (de)
HK (1) HK1002010A1 (de)
HU (1) HU229023B1 (de)
IL (1) IL118974A (de)
NO (1) NO306257B1 (de)
NZ (1) NZ299181A (de)
PL (1) PL183468B1 (de)
RU (1) RU2135514C1 (de)
SG (1) SG52834A1 (de)
TR (1) TR199600664A2 (de)
TW (1) TW464654B (de)
ZA (1) ZA966555B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (de) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
JP2001518509A (ja) * 1997-10-06 2001-10-16 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ グルココルチコイド関連機能不全に関連した精神病の処置のための方法。
EP1726307A3 (de) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
WO1999059596A1 (en) 1998-05-15 1999-11-25 The Board Of Trustees Of Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
ES2204613T3 (es) * 1999-04-06 2004-05-01 Akzo Nobel N.V. Androgenos 7-alfa alquilo oralmente activos.
ES2328795T3 (es) * 2001-02-14 2009-11-18 Karo Bio Ab Moduladores del receptor glucocorticoide.
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
HUP0500070A3 (en) * 2001-10-26 2012-09-28 Pop Test Cortisol Llc Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
AU2003291322B2 (en) * 2002-11-05 2008-09-25 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
WO2004069202A2 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
JP5804395B2 (ja) * 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
EP2712317B1 (de) 2011-03-31 2018-09-19 Pop Test Oncology LLC Prävention von infektionen
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3643355A1 (de) 2014-06-03 2020-04-29 Pop Test Abuse Deterrent Technology LLC Zur drahtlosen kommunikation konfigurierte arzneimittelvorrichtung
EP3265127B1 (de) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepriston und octreotid zur verwendung bei der behandlung des cushing-syndroms bei einem patienten mit einem adrenocorticotropen hormon (acth) sezernierenden pankreatischen neuroendokrinen tumor
EP3273983B1 (de) 2015-03-23 2021-05-05 Evestra, Inc. Neuartige cytotoxische wirkstoffe, die vorzugsweise auf den leukämiehemmenden faktor (lif) abzielen, zur behandlung von malignitäten und als neues empfängnisverhütungsmittel
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
WO2017023694A1 (en) * 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
EP3400233A4 (de) * 2015-08-03 2020-02-26 Pop Test Oncology LLC Pharmazeutische zusammensetzungen und verfahren
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394079A4 (de) * 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. Inhibitoren der glucocorticoidrezeptors
US11124537B2 (en) 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3405101B1 (de) 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differentialdiagnose von ektopischem cushing-syndrom
WO2018068021A1 (en) * 2016-10-07 2018-04-12 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3641780A4 (de) 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. Verfahren zur behandlung von neuroepitheltumoren unter verwendung selektiver glucocorticoidrezeptormodulatoren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
WO1995004536A1 (en) * 1993-08-04 1995-02-16 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
DK0683172T3 (da) * 1994-05-19 1998-03-30 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnanderivater

Also Published As

Publication number Publication date
HU229023B1 (en) 2013-07-29
SG52834A1 (en) 1998-09-28
HU9602269D0 (en) 1996-10-28
AU711369B2 (en) 1999-10-14
NO306257B1 (no) 1999-10-11
AR003982A1 (es) 1998-09-30
NO963427L (no) 1997-02-18
EP0763541B1 (de) 1999-07-28
DE69603425T2 (de) 2000-01-20
KR100445376B1 (ko) 2004-11-08
MX9603476A (es) 1997-07-31
PL183468B1 (pl) 2002-06-28
RU2135514C1 (ru) 1999-08-27
ATE182596T1 (de) 1999-08-15
TR199600664A2 (tr) 1997-03-21
DK0763541T3 (da) 2000-02-28
CN1147520A (zh) 1997-04-16
IL118974A0 (en) 1996-10-31
JP3977462B2 (ja) 2007-09-19
HUP9602269A2 (en) 1997-04-28
CZ287740B6 (en) 2001-01-17
ZA966555B (en) 1997-02-19
JPH09104696A (ja) 1997-04-22
CA2182771C (en) 2007-04-24
CZ238696A3 (en) 1997-05-14
HUP9602269A3 (en) 1997-12-29
PL315733A1 (en) 1997-03-03
KR970010784A (ko) 1997-03-27
NZ299181A (en) 1997-09-22
CA2182771A1 (en) 1997-02-18
BR9603429A (pt) 1998-05-12
GR3031116T3 (en) 1999-12-31
US6011025A (en) 2000-01-04
HK1002010A1 (en) 1998-07-24
ES2137625T3 (es) 1999-12-16
DE69603425D1 (de) 1999-09-02
CN1129602C (zh) 2003-12-03
NO963427D0 (no) 1996-08-16
TW464654B (en) 2001-11-21
AU6211996A (en) 1997-02-20
EP0763541A1 (de) 1997-03-19

Similar Documents

Publication Publication Date Title
EP0763541B1 (de) 11-Substituierte Phenyl-estra-4,9-dien Derivate
US4814327A (en) 11 β-(4-isopropenylphenyl)estra-4,9-dienes, their production, and pharmaceutical preparations containing same
US5095129A (en) 19,11 β-bridged steroids, their manufacture and pharmaceutical preparations containing them
US5620966A (en) 11,21-bisphenyl-19-norpregnane derivatives
US5854235A (en) 17-spiromethylene steroids
US5292878A (en) 17-spirofuran-3'-ylidene steroids
HU191739B (en) Process for producing 11-beta-estradiene derivatives and pharmaceutical compositions containing them
EP0413269B1 (de) 4-Substitutiertes 17-beta-(Cyclopropyloxy)androst-5-en-3-beta-ol und seine Derivate, verwendbar als Inhibitoren der C17-20-Lyase
RU2187510C2 (ru) Производные 16-гидрокси-11-(замещенный фенил)-эстра-4,9-диена, соединение, фармацевтическая композиция
IE43742B1 (en) 15 steroids
EP0567469B1 (de) 14beta-H-, 14- UND 15-EN-11beta-ARYL-4-ESTRENE
KR0160280B1 (ko) 19-하이드록실라제 억제제로 유용한 19-치환된 프로게스테론 유도체
US5446178A (en) Process for preparing 19,11β-bridged steroids
MXPA96003476A (es) Derivados de 11-(fenilo sustituido)-estra-4,9-dieno
DE19535851A1 (de) 18-Norsteroide mit gestagener Wirkung

Legal Events

Date Code Title Description
HK Corrigendum

Free format text: CORRECT THE CONVENTION COUNTRY TO: EP

KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees